<DOC>
	<DOC>NCT02492815</DOC>
	<brief_summary>Observational study to evaluate the effectiveness and safety of ipilimumab, administered during the European expanded access programme (EAP) in pretreated patients with advanced (unresectable or metastatic) melanoma.</brief_summary>
	<brief_title>PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma</brief_title>
	<detailed_description>Minimum age: 18 years old (at time of inclusion in the CA184-367- but 16 for the EAP)</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients have been enrolled in the EAPs Patients still alive must provide informed consent if required by local regulations Deceased patients are eligible per local regulations, their legal representatives must provide informed consent if required by local regulations There are no specific exclusion criteria in this observational study other than the exclusion criteria of the EAP</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>